RAP1GAP2

Across TCGA pan-cancer cohorts, RAP1GAP2 RNA differs between tumor and matched normal tissue in 14 of 18 cancer types tested, making tumor–normal expression one of RAP1GAP2’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where RAP1GAP2 RNA is repressed in tumor relative to normal tissue. In most cancer types RAP1GAP2 is over-expressed in tumor, although a few such as KIRC and UCEC show the opposite, repressed pattern.

KIRC, THCA, and COAD are the cancer types where RAP1GAP2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RAP1GAP2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	II,III,IV	−1.397	<.001	11	view →
THCA	Male	All	+0.573	<.001	8	view →
COAD	Male	All	+0.540	.020	7	view →
CHOL	Female	All	+3.420	<.001	5	view →
LIHC	All	II,III,IV	+0.620	.004	5	view →
STAD	Male	II,III,IV	+0.869	.004	4	view →
UCEC	All	All	−0.541	.020	4	view →
LUAD	Male	II,III,IV	+1.073	<.001	3	view →
PRAD	All	All	+0.903	<.001	2	view →
HNSC	Male	III,IV	+0.858	.011	2	view →
BRCA	Female	All	−0.349	.014	2	view →
BLCA	All	III,IV	+0.971	.031	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 14 lineages.

RAP1GAP2–KIRC

Open the KIRC breakdown →